![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » VBL Therapeutics’ Investigational Drug Ofra-Vec Fails Phase 3 Trial
VBL Therapeutics’ Investigational Drug Ofra-Vec Fails Phase 3 Trial
VBL Therapeutics’ investigational drug ofra-vec (ofranergene obadenovec; VB-111) failed to show promise in a late-stage study for treatment of platinum-resistant ovarian cancer.
In the phase 3 trial, the combined ofra-vec plus paclitaxel treatment did not show meaningful improvements in progression-free survival and overall survival, the study’s primary endpoints.
VBL has decided to discontinue the study and shift its focus to ongoing phase 2 clinical trials to determine ofra-vec’s possible uses in metastatic colorectal cancer and recurrent glioblastoma multiforme.
“Given the urgent unmet need for those fighting platinum-resistant ovarian cancer, we are deeply disappointed that the top-line data indicate that ofra-vec did not improve progression free survival or overall survival,” said VBL CEO Dror Harats.
Upcoming Events
-
18Jul
-
21Oct